XOMA Royalty Corporation (XOMA)

In March 2026, XOMA Royalty reported its fourth quarter and full-year 2025 financial results, which included an earnings per share (EPS) of $0.26 and revenue of $13.76 million. This strong performance led to a stock jump of over 5% in pre-market trading. In February 2026, XOMA Royalty announced the closing of a tender offer and the completed acquisition of Generation Bio, Inc. In January 2026, the company announced changes in its CFO position. Throughout 2025, XOMA Royalty repurchased and retired 648,048 shares of its common stock for an aggregate of $16.0 million as part of a stock buyback program. The company's stock price has shown significant appreciation, increasing by 62.54% from April 1, 2025, to March 31, 2026. As of April 8, 2026, the stock price was up 30.35% year-to-date.

The demand for XOMA Royalty Corp.'s royalty streams does not exhibit traditional seasonality. Instead, the revenue streams are tied to the clinical development and commercialization timelines of the underlying drug candidates, which are managed by partner companies. Therefore, demand seasonality in the conventional sense is not directly applicable to XOMA Royalty Corp.'s operations.

XOMA Royalty Corp. operates as a biotechnology royalty aggregator, providing non-dilutive funding to biotech companies. The company acquires economic rights to future milestone and royalty payments associated with pre-commercial clinical candidates and commercial therapeutic products. XOMA Royalty Corp. is primarily situated within the Healthcare sector, specifically in the Pharmaceuticals industry, with sub-industries including Molecular Science, Genetics & Gene Therapy, and Pharmaceutical Research & Development. The company's portfolio comprises over 120 assets, which are licenses providing rights to potential future royalty and milestone payments. Key commercial products from which XOMA Royalty derives economic rights include VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA®.

XOMA Royalty Corp. has a global geographic footprint, operating in the United States, Switzerland, the Asia Pacific region, Europe, and Australia. The company serves clients in North America and Europe and aims to expand its reach into additional regions across these continents.

XOMA Royalty Corp. has worked to cement its reputation as a unique source of capital for biotech innovation. The company's strategy of acquiring economic rights to milestone and royalty payments provides non-dilutive funding to biotech firms. However, the company has also been involved in ongoing litigation against Janssen Biotech, Inc., asserting claims for breach of contract and unjust enrichment arising from Janssen's alleged unauthorized use of XOMA's intellectual property in the commercialization of TREMFYA.

XOMA Royalty Corp. has a significant institutional ownership, with 76 institutional owners holding a total of 8,634,107 shares as of April 8, 2026. Major institutional shareholders include BVF Inc/il, Morgan Stanley, Fmr Llc, Vanguard Group Inc, BlackRock, Inc., Opaleye Management Inc., Woodline Partners LP, Geode Capital Management, Llc, State Street Corp, and Stonepine Capital Management, LLC. Institutional investors collectively own 46% of the company, with hedge funds holding 22% of the shares. The largest shareholder is BVF Partners L.P., with 22% ownership. Individual investors, or the general public, hold a 31% stake. Insiders own approximately 9.10% of the stock.